Scholarlink

<p>Gallbladder cancer (GBC) is a highly aggressive biliary tract tumor with a poor prognosis, underscoring the critical need for new therapeutic strategies. N-acetyltransferase 10 (NAT10), the sole writer of N4-acetylcytidine (ac4C), is upregulated in multiple cancers and is implicated in tumor pathogenesis. We observed significant NAT10 overexpression in GBC. Functional studies confirmed that NAT10 drives growth, migration, and malignant progression of GBC cells. We mechanistically linked this to NAT10-mediated ac4C modification, which stabilizes proprotein convertase subtilisin/kexin type 9 (PCSK9) mRNA, thereby reprogramming cholesterol metabolism and triggering intracellular cholesterol accumulation. This cholesterol buildup subsequently activates the PI3K/AKT pathway, stimulating cancer cell proliferation, migration, and invasion. Therapeutically, targeting NAT10 with Remodelin potently suppressed GBC proliferation. Importantly, Remodelin synergized with the standard chemotherapeutic agent gemcitabine to markedly enhance its therapeutic effect. Thus, our study defines a novel mechanism in which NAT10-dependent ac4C modification stabilizes PCSK9 mRNA to promote cholesterol-driven malignancy, nominating NAT10 as a compelling therapeutic target in GBC.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

NAT10 promotes gallbladder cancer progression by remodeling cholesterol metabolism via PCSK9 mRNA acetylation

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月16日

查看全文
  • Zheng-yu Chen,
  • Ming-yang Wang,
  • Ben Ma,
  • Cheng Zhao,
  • Li-jia Pan,
  • Zi-ying Wang,
  • Yu-ting Wang,
  • Pan-yi Mao,
  • Xiang Zhao,
  • De-long Qin,
  • Yi-jun Shu,
  • Yun-jiao Zhang,
  • Shan-shan Xiang,
  • Ping Dong

摘要

Gallbladder cancer (GBC) is a highly aggressive biliary tract tumor with a poor prognosis, underscoring the critical need for new therapeutic strategies. N-acetyltransferase 10 (NAT10), the sole writer of N4-acetylcytidine (ac4C), is upregulated in multiple cancers and is implicated in tumor pathogenesis. We observed significant NAT10 overexpression in GBC. Functional studies confirmed that NAT10 drives growth, migration, and malignant progression of GBC cells. We mechanistically linked this to NAT10-mediated ac4C modification, which stabilizes proprotein convertase subtilisin/kexin type 9 (PCSK9) mRNA, thereby reprogramming cholesterol metabolism and triggering intracellular cholesterol accumulation. This cholesterol buildup subsequently activates the PI3K/AKT pathway, stimulating cancer cell proliferation, migration, and invasion. Therapeutically, targeting NAT10 with Remodelin potently suppressed GBC proliferation. Importantly, Remodelin synergized with the standard chemotherapeutic agent gemcitabine to markedly enhance its therapeutic effect. Thus, our study defines a novel mechanism in which NAT10-dependent ac4C modification stabilizes PCSK9 mRNA to promote cholesterol-driven malignancy, nominating NAT10 as a compelling therapeutic target in GBC.